Kenan Çevik, Mustafa Ertan Ay, Özlem İzci, Anil Ay, Didem Derici Tombak, Yildirim Tuba, Kabasakal, Mehmet Emin, Erdal
{"title":"多发性骨髓瘤患者骨髓中 hsa-miR-29 家族及其靶基因的表达水平和临床意义","authors":"Kenan Çevik, Mustafa Ertan Ay, Özlem İzci, Anil Ay, Didem Derici Tombak, Yildirim Tuba, Kabasakal, Mehmet Emin, Erdal","doi":"10.56042/ijeb.v61i12.2999","DOIUrl":null,"url":null,"abstract":"The microRNA (miR)-29 family has been deregulated in several types of hematologic malignancies. However, role of this family and their target genes DNMT3A (DNA methyltransferase 3A) and TET2 (Ten-Eleven Translocation 2) remains unclear. Here, we have made an attempt to determine the relative expression levels of three miRNAs and target genes in patients with newly diagnosed Multiple myeloma (MM) using quantitative real-time PCR. Moreover, the expression levels of selected miRNAs and genes and their correlations with clinical parameters were compared and analyzed. The ROC curve was used to analyze their diagnostic efficacy for MM. The expression level of hsa-miR-29b-3p was significantly higher in patients with newly diagnosed MM compared with the control group. ROC analysis showed that hsa-miR-29b-3p demonstrated a moderate diagnostic power in MM. The relative expression level of hsa-miR-29b-3p in patients with high LDH levels was markedly reduced compared to that in patients with normal and low LDH levels . DNMT3A expression level was significantly increased in patients with high LDH levels and patients with lambda light chain. Our results indicate that hsa-miR-29b-3p may be used as a potential biomarker in the diagnosis of MM.","PeriodicalId":13290,"journal":{"name":"Indian journal of experimental biology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression levels and clinical significances of hsa-miR-29 family and their target genes in the bone marrow of patients with multiple myeloma\",\"authors\":\"Kenan Çevik, Mustafa Ertan Ay, Özlem İzci, Anil Ay, Didem Derici Tombak, Yildirim Tuba, Kabasakal, Mehmet Emin, Erdal\",\"doi\":\"10.56042/ijeb.v61i12.2999\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The microRNA (miR)-29 family has been deregulated in several types of hematologic malignancies. However, role of this family and their target genes DNMT3A (DNA methyltransferase 3A) and TET2 (Ten-Eleven Translocation 2) remains unclear. Here, we have made an attempt to determine the relative expression levels of three miRNAs and target genes in patients with newly diagnosed Multiple myeloma (MM) using quantitative real-time PCR. Moreover, the expression levels of selected miRNAs and genes and their correlations with clinical parameters were compared and analyzed. The ROC curve was used to analyze their diagnostic efficacy for MM. The expression level of hsa-miR-29b-3p was significantly higher in patients with newly diagnosed MM compared with the control group. ROC analysis showed that hsa-miR-29b-3p demonstrated a moderate diagnostic power in MM. The relative expression level of hsa-miR-29b-3p in patients with high LDH levels was markedly reduced compared to that in patients with normal and low LDH levels . DNMT3A expression level was significantly increased in patients with high LDH levels and patients with lambda light chain. Our results indicate that hsa-miR-29b-3p may be used as a potential biomarker in the diagnosis of MM.\",\"PeriodicalId\":13290,\"journal\":{\"name\":\"Indian journal of experimental biology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian journal of experimental biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.56042/ijeb.v61i12.2999\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of experimental biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.56042/ijeb.v61i12.2999","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOLOGY","Score":null,"Total":0}
Expression levels and clinical significances of hsa-miR-29 family and their target genes in the bone marrow of patients with multiple myeloma
The microRNA (miR)-29 family has been deregulated in several types of hematologic malignancies. However, role of this family and their target genes DNMT3A (DNA methyltransferase 3A) and TET2 (Ten-Eleven Translocation 2) remains unclear. Here, we have made an attempt to determine the relative expression levels of three miRNAs and target genes in patients with newly diagnosed Multiple myeloma (MM) using quantitative real-time PCR. Moreover, the expression levels of selected miRNAs and genes and their correlations with clinical parameters were compared and analyzed. The ROC curve was used to analyze their diagnostic efficacy for MM. The expression level of hsa-miR-29b-3p was significantly higher in patients with newly diagnosed MM compared with the control group. ROC analysis showed that hsa-miR-29b-3p demonstrated a moderate diagnostic power in MM. The relative expression level of hsa-miR-29b-3p in patients with high LDH levels was markedly reduced compared to that in patients with normal and low LDH levels . DNMT3A expression level was significantly increased in patients with high LDH levels and patients with lambda light chain. Our results indicate that hsa-miR-29b-3p may be used as a potential biomarker in the diagnosis of MM.
期刊介绍:
This journal, started in 1963, publishes full papers, notes and reviews in cell biology, molecular biology, genetic engineering, endocrinology, reproductive biology, immunology, developmental biology, comparative physiology, radiation biology, chronobiology, microbiology, pharmacology, toxicology and other biological fields including instrumentation and methodology. The papers having experimental design involving alteration and/or manipulation in biological system(s) providing insight into their functioning are considered for publication. Studies involving higher animals, human beings and of clinical nature are not encouraged for publication in the journal.